Cyprotex PLC Expansion of Drug Transporter Capabilities
October 09 2014 - 1:01AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
09 October 2014
9 October 2014
Cyprotex PLC
Expansion of Drug Transporter Capabilities
Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research
Organisation (CRO), today announces the expansion of its in-house
drug transporter services. Cyprotex can now offer the full range of
in vitro drug transporter assays that are recommended by the
regulatory authorities in a high quality, robust, and timely
manner.
Industry knowledge of drug transporters and how they influence
drug interactions is growing rapidly. New regulatory guidance
released by the US Food and Drug Administration (FDA) and European
Medicines Agency (EMA) in 2012, as well as a publication by the
International Transporter Consortium in 2013, is guiding the future
direction in this field. The regulatory authorities recommend
screening those transporters which play a key role in potential
clinical drug interactions using in vitro cell based assays. A
range of transporters have now been implicated in clinical
drug-drug interactions (including P-gp, BCRP, OATP1B1, OATP1B3,
OAT1, OAT3 and OCT2), and this range will continue to expand as new
research is published.
Recent investments in the transporter services offered at the
Cyprotex site at Biohub Alderley Park include the purchase of a
PerkinElmer MicroBeta(R) scintillation counter and a LabLogic
Beta-RAM(R) . At this site, Cyprotex has gained a permit to store,
handle and dispose of radiolabelled material which is essential for
the transporter services and allows Cyprotex to expand their
service offerings into new areas where use of radiolabelled
material is important.
The drug transporter team at Cyprotex includes highly
experienced scientists who have worked previously in the field of
drug transporter research, adding to an already strong
bioanalytical team which is well equipped with the latest
technology for analysing a range of different chemistries. Robust
sample analysis is an important stage in these studies,
particularly for data submitted to the regulatory authorities.
Commenting on the launch of the new transporter facility, Dr
Anthony Baxter, CEO of Cyprotex said: "Developing a transporter
facility is critical to maintain our position as leaders in the
ADME-Tox field. Cyprotex have created a centre of excellence in
this area which combines highly experienced scientists with robust
quality science and communication. Our comprehensive range of
state-of-the-art bioanalytical equipment, knowledge and expertise
in the bioanalytical field ensures that we have the best chance of
detecting and analysing even the most challenging molecules. We
will ensure that our range of assays in this area will continue to
expand in line with regulatory guidance and customer demand."
For further information:
Cyprotex PLC Tel: +44 (0) 1625 505
100
Dr Anthony Baxter, Chief Executive Officer ir@cyprotex.com
John Dootson, Chief Financial Officer www.cyprotex.com
Mark Warburton, Chief Operating Officer
and Legal Counsel
N+1 Singer (Nomad and broker to Cyprotex) Tel: +44 (0)20 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
FTI Consulting Tel: +44 (0) 20 3727 1000
Simon Conway cyprotex@fticonsulting.com
Mo Noonan www.fticonsulting.com
Notes to Editors
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 900 partners within the pharmaceutical and
biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services, extending from early drug discovery through to IND
submission. The acquisition of the assets and business of CeeTox in
January 2014 has enabled Cyprotex to expand its range of services
to target the personal care, cosmetics and chemical industries. The
Company's core capabilities include high quality in vitro ADME
screening services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, predictive modelling
using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK
prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFVEIDLTIIS
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024